Volume 93, Number 7
Treatment-refractory hypothyroidism: Don’t just increase the dose

How to Obtain AMA PRA Category 1 Credit™ and ABIM MOC points
- Review information on this page.
- Read the journal article.
- Return to this page and select the "Complete the CME/MOC Process" link.
- Login to your myCME account.
- If claiming MOC, choose the 'CME & MOC' option and complete the posttest.
- Complete the registration / evaluation form.
- Print your personalized CME/MOC certificate.
Release Date: July 1, 2026
Expiration Date: June 30, 2027
Estimated Time of Completion: 1 hour
Description
Treatment-refractory primary hypothyroidism has been defined as a persistently elevated serum thyroid-stimulating hormone level despite prescriptions for levothyroxine in high oral doses.
Disclosures
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they have a relationship which, in the context of their contributions, could be perceived as a potential conflict of interest:
| Brian F. Mandell, MD, PhD (Activity Director) | ||
| Consulting | Amgen, Horizon Pharma | |
| Research: PI local site | Amgen, Arthrosi Pharma | |
| Teaching and Speaking | Arthrosi Pharma | |
| Advisor or review panel participant | Arthrosi Pharma | |
| Data Monitoring Safety Board | Wave Therapeutics | |
| Adam J. Brown, MD | ||
| Consulting | Amgen, Sanofi | |
| Teaching and speaking | Amgen, Sanofi | |
| Abhijit Duggal, MD | ||
| Advisor or review panel participant | Alung Technologies | |
| Yuebing Li, MD | ||
| Research: Principal investigator | Alexion, Argenx, Immunovant, Johnson & Johnson, Vertex Pharmaceuticals | |
| Member of Clinical Practice Scientific Advisory Board | Alexion | |
| Consulting | Amgen, Argenx, Immunovant, Johnson & Johnson, Vertex Pharmaceuticals | |
| Christian Nasr, MD | ||
| Advisor or review panel participant | Horizon Therapeutics, Viridian Therapeutics | |
| Jennifer S. Mammen, MD, PhD | ||
| Consulting | Amgen | |
| Research: Principal investigator | Interpace Diagnostics | |
All other authors, co-activity directors, reviewers and CCJM staff report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.
(Article opens in a new tab / window; return to this window to complete the activity).
This CME activity was produced by the Cleveland Clinic Journal of Medicine and the Cleveland Clinic Center for Continuing Education.

